Introduction
Green tea, made from the unfermented leaves of Camellia sinensis, is comprised of several polyphenolic compounds (catechins) and can be concentrated into a green tea extract (GTE), which, in turn, is a common ingredient in many dietary supplements.
Epigallocatechin-3-gallate (EGCG) is the most abundant and potent catechin contained within GTE, comprising typically ~40% of the total polyphenol content. 1 EGCG has antioxidant, antiviral anticarcinogenic, antimutagenic, and anti-inflammatory properties,
shown in several preclinical and epidemiologic studies . [2] [3] [4] [5] [6] Preclinical data in cell culture and animal models suggest green tea may have a role as a chemopreventative agent for many types of cancer, including hepatocellular carcinoma (HCC). [7] [8] [9] [10] After oral absorption, tea catechins undergo extensive methylation, glucuronidation, and sulfation. Rapid methylation of EGCG is catalyzed by liver cytosolic catechol-O-methyltransferase. Methylation decreases the hydrophilicity of catecholic compounds; further sulfation/glucuronidation of the methylated product is usually needed for the elimination of the product from the body. 11, 12 There has been discussion that level of methylation is influenced by polymorphisms of catechol-Omethyltransferase, but the effect of this has not yet been fully studied. Within the plasma, serum albumin contributes to transport and stabilization by directly preventing EGCG oxidation. Therefore, low serum albumin may decrease EGCG plasma levels. 13 The safety and pharmacokinetics of EGCG in patients with cirrhosis has not been described. This may reflect concerns regarding a risk for hepatotoxicity with EGCG, especially where such risk may be unpredictable due to differences in EGCG's disposition in this patient population as a result of the underlying liver disease. Reports of hepatitis associated with the consumption of green tea preparations have been published. [14] [15] [16] The mechanism of the potential hepatotoxicity of GTE is unclear. 13 However it can be hypothesized that the impact of a hepatotoxic event may be magnified in patients with preexisting liver disease as a result of alterations in pathways involved in EGCG's hepatic metabolism or excretion. Differences in the disposition of silymarin, another herbal product used by patients for the self-treatment of liver disease, has been seen in liver disease. 17, 18 Alterations in the expression of hepatobiliary transporters induced by liver disease, which may lead to differences in drug disposition, have been reported. 19 The risk of hepatic decompensation as a result of drug induced liver injury is greatest in patients with cirrhosis and increases with disease progression defined by Child Pugh classification . 20 The main goal of this study was to estimate EGCG exposure following a single oral dose of a green tea extract highly concentrated base EGCG, using a limited pharmacokinetic sampling schedule, in Child Pugh class A and B patients, and in non-cirrhotic patients with HCV. Furthermore, this study establishes the safety and tolerability of EGCG at the dose selected and serves as rationale for larger scale dose escalation and multiple dose studies in this potentially vulnerable population.
Patients and Methods

Study Participants
Adult patients with HCV viremia, and cirrhosis status assessed by prior biopsy or imaging were recruited from Thomas Jefferson University Hepatology practice for inclusion in the study. Exclusion criteria were prior liver transplantation, hepatocellular cancer, and current HCV treatment.
Study Protocol
This was an open label, single dose, clinical trial. The study protocol was approved by the Thomas Jefferson University Institutional Review Board and all study subjects provided written informed consent. Subjects were asked to refrain from ingestion of tea or tea containing products for 14 days prior to the day of the study. The day before the study participants were instructed to fast after midnight except for drinking water. Subjects were fed 4 hours after dosing. The fasting condition and sampling times were based on previously published limited sampling strategy models which had greater predictive performance under fasting conditions and were shown to accurately predict EGCG oral clearance in healthy subjects. 21 Follow up safety labs were drawn 8 to 15
days after dosing.
Analysis of EGCG Plasma Concentrations
Plasma samples for EGCG were analyzed using LC-MS with negative ion electrospray ionization. The assay has a detection limit of 2ng/ml and is linear in the range of 2-5000ng/ml. The accuracy for EGCG quantification was 79.8% and intra-and interday precisions were 1.7 to 7.9% and 3.7 to 9.6%, respectively.
Pharmacokinetic Analysis
Estimated area under the curve for the limited sampling strategy (AUC LSS 0→10 ) was calculated with the trapezoidal rule. Half-life (t 1/2 ) was calculated from the measurements obtained at 4 and 10 hours post-dosing. Geometric means for AUC and t 1/2 were computed for cirrhotics and non-cirrhotic controls, along with 95% confidence intervals, but the small sample sizes precluded a direct statistical comparison. The analyses were conducted in SAS 9.3.
Results:
Eleven subjects were enrolled; four with Child-Pugh Class A, four with ChildPugh class B, and three non-cirrhotic subjects ( Table 1 ). The median EGCG concentrations and pharmacokinetic estimates are summarized in Table 2 and Figure 1 ...
The C max was 89 ng/ml in non-cirrhotics at 2 hours; 182 ng/ml at 2 hours in cirrhotics.
The AUC increased with more advanced liver disease; that is, the exposure to EGCG was higher in cirrhotic patients than in the noncirrhotic patients. Three patients had detectable EGCG noted on baseline EGCG concentration labs. Upon later questioning, the subjects reported tea intake (not labeled as green tea) despite being asked to refrain from tea for 14 days prior to the study day. One class B cirrhotic had highly increased EGCG concentrations at baseline that were unable to be verified; therefore, these the data from this subject were excluded from final analysis. Figure 1 shows EGCG concentration over dosing day. Of note, Child Pugh subject A3 appeared to have an exposure greater than any other subject. No drug related adverse events were reported during the study or at the follow up safety visit. Two of the four Child-Pugh Class B subjects had a rise in their total bilirubin (over 2 mg/dL) noted on follow up safety labs drawn 8 to 15 days after dosing day, although these elevations were within the patients' observed retrospective range.
Discussion:
In this study we provide the first description of EGCG pharmacokinetics in patients with chronic HCV infection. The rationale for the study is predicated upon EGCG's potential therapeutic benefit in this patient population; specifically, its antiviral and antitumor effects. However, given the hepatotoxic potential of green tea extract and the potential for augmented hepatotoxicity in patients with chronic liver disease, it is important to have established safety and tolerability, even if only at one dose, before proceeding to additional studies. While point estimates of EGCG AUC suggest systemic exposure that is higher in cirrhotics than in non-cirrhotics, the relatively small number of patients, PK collection samples, and intersubject variability suggest that the study is underpowered to detect a true difference, should one exist. This study presents exploratory data only; future studies will need to incorporate more subjects. However, the data do provide a broad estimate of EGCG disposition in this population, and show overlap between the three study panels.
Approximately 2% of the US population is infected with HCV; cirrhosis develops in 20% of those infected and HCC develops in 25% of cirrhotics, most of whom die from their disease. 8, 22 EGCG has been found to be a potent inhibitor of HCV entry in hepatoma cell lines as well as primary human hepatocytes. 23, 24 Beyond its antiviral effect on HCV, Since 1966, 216 case reports of toxicity with green tea extracts were identified by the United States Pharmacopeia, of which 34 were concerning for liver toxicity. 13 The majority of cases present with an acute hepatocellular injury pattern and most recover with cessation of use. 12, 26, 27 Based on this review, no significant safety issues were identified that would prohibit further development of green tea extract containing dietary supplements. An idiosyncratic or an immune-allergic mechanism appears to be the likely mechanism of injury. Recent animal studies with high doses of GTE and EGCG have described dose dependent hepatotoxicity resulting in severe morbidity and mortality. 28 However, chronic moderate to high dose daily GTE and EGCG use in healthy human volunteers was not shown to cause severe adverse effects or impair liver function. [29] [30] [31] [32] Prior pharmacokinetic studies have established peak blood concentrations and exposures of EGCG associated with its safety and tolerability in healthy subjects. [30] [31] [32] [33] [34] In a study by Chow et al., following a single 800mg dose of EGCG in five healthy volunteers, AUC (min·µg/ml) ±SD was 167.1 ± 57.0, C max (ng/mL) was 438.5 ± 28.4 and t 1/2 (min) was 114.0 ± 33.3. 35 In a multi-dose study by Chow et al., volunteers were randomly assigned to receive one of the five treatments for 4 weeks: 800 mg EGCG once/day, 400 mg EGCG twice/day, 800 mg EGCG as Polyphenon E once/day, 400 mg EGCG as Polyphenon E twice/day, or a placebo once/day (8 subjects/group). There was a >60% increase in the area under the plasma EGCG concentration-time curve after 4 weeks of green tea polyphenol treatment at a dosing schedule of 800 mg once daily. No significant changes were observed in the pharmacokinetics of EGCG after repeated green tea polyphenol treatment at a regimen of 400 mg twice daily. The described dose range, which was equivalent to 8-16 cups of green tea/day, and frequency of administration of EGCG in these study appeared to be well tolerated. 30 The EGCG dosing in these pharmacokinetic studies is similar to the chronic dosing studies noted above which also showed no hepatotoxicity. The half life estimates were unchanged across patient populations, and were similar to those noted by Chow in healthy subjects. In comparison, the point estimates of AUC [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] were larger in cirrhotics compared to non-cirrhotics (1281 vs. 670 min•ng/ml), though there was significant overlap and these differences were not statistically significantly different.
A limitation of this study is the fact that baseline EGCG levels were detectable in a few patients at low levels despite being asked to refrain from green tea products. These low values that did not materially impact the pharmacokinetic parameter estimation. While there was intersubject variability noted in the AUC 0-10 value, there does appear to be suggestion of a disease severity related effect on systemic exposure at similar doses of orally administered GTE. The mechanism by which this could occur could be increased extent of absorption or enterohepatic recirculation. Alternatively, decreased total clearance would need to be paired with an increase in volume of distribution to maintain an unchanged t 1/2 . The current study does not provide guidance about the mechanism by which the currently observed differences could be explained.
Conclusions:
Overall, a single 400 mg oral dose of EGCG was safe and well tolerated. However, due to our small sample size and variability in pharmacokinetic exposures, detection of exposure differences or hepatotoxicity risk between were not identified. In addition, the single dose design of our study does not allow for evaluation of dose-and time-dependent hepatotoxicity risk. Overall, the exposures observed in our study suggest that the disposition of EGCG is not significantly altered in patients with cirrhosis; chronic dosing studies should be conducted to define the safety risk in this patient population.
Given its potential role as an adjunct to HCV triple therapy and as a chemopreventative agent in the HCV cirrhotic population, our findings support the conduct of a Phase I chronic dose-escalation study and multiple dose study eventually leading to a large-scale efficacy and chemoprevention trials. In light of the hepatotoxic potential of EGCG, future studies should be limited to patients with early stage (Childs Pugh Class A) cirrhosis, who remain at risk for HCC, who are monitored carefully for early signals of hepatotoxicity.
